DUBLIN, March 3, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) ("Allergan") confirms that, as of the close of business on March 2, 2020, Allergan's issued share capital, excluding treasury shares, consisted of 329,125,399 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). The International Securities Identification Number (ISIN) of the Allergan Ordinary Shares is IE00BY9D5467.

DUBLIN, Feb. 25, 2020 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology, will present new data from investigational Bimatoprost Sustained-Release (SR) at the Annual Meeting of the American Glaucoma Society (AGS) to be held in Washington, D.C. Data from the Phase 3 ARTEMIS studies will be presented during an oral session and will provide visual field (VF) outcomes and effects of Bimatoprost SR on disease progression in patients with open-angle glaucoma (OAG). A New Drug Application (NDA) for Bimatoprost SR is currently under review with the U.S. Food and Drug Administration, and if approved, has the potential to be the first and only biodegradable, intracameral implant indicated to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension via a sustained-release drug delivery system.

DUBLIN, Feb. 14, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) ("Allergan") confirms that, as of the close of business on February 13, 2020, Allergan's issued share capital, excluding treasury shares, consisted of 328,998,524 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). The International Securities Identification Number (ISIN) of the Allergan Ordinary Shares is IE00BY9D5467.

DUBLIN, Feb. 14, 2020 /PRNewswire/ -- 1.  KEY INFORMATION 2.  INTERESTS AND SHORT POSITIONS (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

DUBLIN, Feb. 10, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its full-year and fourth quarter 2019 financial results including full-year 2019 GAAP net revenues of $16.1 billion, a 1.9 percent increase from 2018. Fourth quarter 2019 GAAP net revenues were $4.35 billion, a 6.6 percent increase from the prior year quarter.

DUBLIN, Feb. 3, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today its Be The Difference philanthropic program supporting children and their families who may benefit from treatment with BOTOX^® (onabotulinumtoxinA) for pediatric upper limb spasticity. BOTOX^® is approved to treat increased muscle stiffness in children 2 to 17 years of age with upper limb spasticity. BOTOX^® Cosmetic is approved for three aesthetic indications and BOTOX^® is approved for 11 therapeutic indications in the U.S. During the month of February, every BOTOX^® Cosmetic treatment recorded in Brilliant Distinctions^®, Allergan's loyalty reward program, will help Allergan contribute up to a total of $500,000 to Foundations that help children across the country.

DUBLIN, Jan. 31, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release fourth quarter and full year 2019 financial results on Monday, February 10, 2020, prior to the open of U.S. financial markets. For additional materials related to Allergan's fourth quarter and full year 2019 financial results, please visit Allergan's Investor Relations website at https://www.allergan.com/investors.

DUBLIN, Jan. 30, 2020 /PRNewswire/ --  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) ("Allergan") confirms that, as of the close of business on January 28, 2020, Allergan's issued share capital, excluding treasury shares, consisted of 328,763,705 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). The International Securities Identification Number (ISIN) of the Allergan Ordinary Shares is IE00BY9D5467.

DUBLIN, Jan. 24, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the first quarter of 2020. The dividend will be paid on March 13, 2020 to shareholders of record at the close of business on February 14, 2020.

DUBLIN, Jan. 17, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today the launch of the SkinMedica^® Instant Bright Eye Cream, a refreshing eye treatment that hydrates, brightens and helps visibly firm the appearance of the delicate skin around the eyes. The product is designed to immediately improve the appearance of the eyes and continues reducing the visible signs of aging and fatigue over time—including dark circles, fine lines and crepiness of upper eyelids.  For its most comprehensive regimen, SkinMedica^® is also introducing Instant Bright Eye Mask, a set of hydrogel eye patches that reduce the appearance of puffiness and provide a hydrating boost for under the eyes.